More on BMRN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $60.57 |
|
|||
| Open | $60.23 | ||||
| 52 Wk High | $108.96 | ||||
| 52 Wk Low | $62.12 | ||||
| Day High | $61.52 | ||||
| Day Low | $59.16 | ||||
| P/E | N/A | ||||
| EPS | $-1.27 | ||||
| Volume | 2,630,907 | ||||
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
- Truist Securities Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
- BioMarin Pharmaceutical (BMRN) Reiterated at Overweight by Cantor Fitzgerald After Webinar
- U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
- Form 4 BIOMARIN PHARMACEUTICAL For: Feb 25 Filed by: Guyer Charles Greg
- Form 4 BIOMARIN PHARMACEUTICAL For: Feb 26 Filed by: Friberg Gregory R
- Form 4 BIOMARIN PHARMACEUTICAL For: Feb 25 Filed by: Davis George Eric
- Form 4 BIOMARIN PHARMACEUTICAL For: Feb 25 Filed by: Mueller Brian
- Form 144 BIOMARIN PHARMACEUTICAL Filed by: Friberg Gregory R
Entities mentioned with BMRN
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Show More...
